HLA class-I genotyping to personalize Bacille Calmette–Guerin immunotherapy in bladder cancer

Bacille Calmette-Guerin (BCG) is the immunotherapy of choice for high-risk non-muscle invasive bladder cancer (BC), although recurrence eventually occurs in 50% of patients and 20% progress to advanced stages. This study evaluates the predictive value of human leukocyte antigen class-I (HLA-I) genot...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Inmaculada Ruiz-Lorente, Lourdes Gimeno, Alicia López-Abad, Pedro López Cubillana, Tomás Fernández Aparicio, Lucas Jesús Asensio Egea, Juan Moreno Avilés, Gloria Doñate Iñiguez, Pablo Luis Guzmán Martínez-Valls, Gerardo Server, Belén Ferri, José Antonio Campillo, Francisco Galindo, María Victoria Martínez-Sánchez, Alfredo Minguela
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2025-12-01
Serie:	OncoImmunology
Soggetti:	Bladder cancer Bacille Calmette-Guerin immunotherapy NK cells HLA
Accesso online:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2598920
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!